SCOLR Pharma (DDD) Announces Positive Results from Its Second 24 Hour CDT-Ondansetron Trial; Discontinues Development of Extended Release Phenylephrine

February 6, 2007 3:05 PM EST

SCOLR Pharma, Inc. (AMEX: DDD) announced positive preliminary results from pilot bioavailability testing of its refined 24-hour CDT-based ondansetron tablets.

The Company also reported that it will no longer continue the development of a 12-hour CDT-based phenylepherine formulation.

Daniel O. Wilds, President and CEO of SCOLR Pharma, said, "While we are disappointed that our initial work on an extended release phenylepherine formulation does not support further commercial development, the successful completion of our second ondansetron study represents the achievement of another important milestone for our Company. The results from our ondansetron study further demonstrate the applicability of our CDT technology to a growing number of challenging compounds and support our optimism that it can be successfully utilized to formulate a broad range of orally-administered pharmaceuticals."

Related Categories

FDA
Hot List

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?